Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ribomic, Inc. ( (JP:4591) ) has provided an update.
RIBOMIC, Inc. announced the sustained efficacy of its drug, umedaptanib pegol, in a long-term administration trial for pediatric patients with achondroplasia. The trial demonstrated that the drug significantly increased the height growth rate of patients, surpassing the current standard treatment, Voxzogo. This development could lead to improved quality of life for individuals with achondroplasia, as the drug targets the disease’s pathogenic mechanism directly. No safety concerns have been reported in the ongoing trials.
More about Ribomic, Inc.
RIBOMIC, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of aptamer therapeutics, a type of nucleic acid medicine. The company utilizes its RiboART system, a core drug discovery platform, to develop drugs for unmet medical needs, including eye diseases and rare childhood diseases such as short stature.
Average Trading Volume: 2,292,784
Technical Sentiment Signal: Buy
Current Market Cap: Yen5.03B
For an in-depth examination of 4591 stock, go to TipRanks’ Overview page.